This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at precision-medicine@magnusconference.com or call + 1 (702) 988 2320.
For thousands of years, pathogens have fought against the host's immunological responses. Pathogens have developed a range of immune evasion methods to prevent immune recognition of infected cells by inhibiting cytokine activity. To regulate viral and bacterial infection, the immune system has developed a variety of strategies, ranging from direct pathogen killing to the development of cytokines that impede replication. The immune system's response to infectious pathogens, as well as how infectious agents interact with, adapt, or evade the immune system, are studied in infectious disease immunology. Our understanding of the immune response to infection has advanced dramatically in recent years.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain